News - ubidecarenone IV (BPM31510 IV)

6ms

BPM31510IV-11: A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB) (clinicaltrials.gov)

P2, N=50, Active, not recruiting, BPGbio | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Aug 2030 | Trial primary completion date: Sep 2025 --> Aug 2026

6 months ago

Enrollment closed • Trial completion date • Trial primary completion date

temozolomide • ubidecarenone IV (BPM31510 IV)

9ms

To explore whether a modified myocardial protection solution containing coenzyme Q10 can improve cardiac function in patients with cyanotic congenital heart disease after cardiac surgery. (ChiCTR2500102959)

P4, N=100, Not yet recruiting, Shanghai Children’s Medical Center, Shanghai Jiaotong University School of Medicine; Shanghai Children's Medical Center, Shanghai Jiaotong Universit

9 months ago

New P4 trial

ubidecarenone IV (BPM31510 IV)

11ms

BPM31510IV-11: A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB) (clinicaltrials.gov)

P2, N=50, Recruiting, BPGbio | Trial primary completion date: Feb 2025 --> Sep 2025

11 months ago

Trial primary completion date

temozolomide • ubidecarenone IV (BPM31510 IV)

almost2years

BPGbio Presents Key Advances in its Oncology Pipeline related to the NAi Interrogative Biology Platform (Businesswire)

"Highlights from posters include: New data further validating the mitochondrial-centric effect of BPM31510 on the immune system. In addition to its direct cell-killing effect on tumor cells, data supports the potential use of BPM31510 in the intersection of tumor immunology and tumor metabolism; BPGbio’s NAi Platform coupled with a subsequent deep learning algorithm implemented on BRG399, a novel pan-cancer drug candidate, can improve efficiency in drug development by rapidly predicting anti-cancer efficacy in silico before conducting resource intensive preclinical experiments."

almost 2 years ago

Preclinical

pstateDx™ test

ubidecarenone IV (BPM31510 IV)

almost2years

A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB) (clinicaltrials.gov)

P2, N=50, Recruiting, Berg, LLC | Trial completion date: May 2026 --> Dec 2025 | Trial primary completion date: Dec 2025 --> Feb 2025

almost 2 years ago

Trial completion date • Trial primary completion date

temozolomide • ubidecarenone IV (BPM31510 IV)

2years

Predictive multi-omics analysis of BPM31510 in combination with gemcitabine in a phase 2 study of advanced pancreatic ductal adenocarcinoma (PDAC). (ASCO-GI 2024)

Clinical Trial Registration Number NCT02650804 Sponsored by No funding sources reported Background: Advanced PDAC has limited therapeutic options. Our results point to biomarkers associated with (a) length on trial, (b) outcome and (c) involvement of mitochondrial biology in the mechanism of BPM31510-IV in the adequately treated PDAC population. The data herein supports further study of these biomarkers in late-stage trials to confirm the biological mechanism of BPM31510 in PDAC patients. Clinical trial information: NCT02650804.

2 years ago

P2 data • Combination therapy • Metastases

CRP (C-reactive protein) • SERPINA5 (Serpin Family A Member 5) • LUM (Lumican)

gemcitabine • ubidecarenone IV (BPM31510 IV)

over2years

A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB) (clinicaltrials.gov)

P2, N=50, Recruiting, Berg, LLC | Trial completion date: Sep 2027 --> May 2026 | Trial primary completion date: Feb 2023 --> Dec 2025

over 2 years ago

Trial completion date • Trial primary completion date

temozolomide • ubidecarenone IV (BPM31510 IV)